NRx Pharmaceuticals' NRX-100 (Ketamine) demonstrated twelve-month real-time stability, a crucial step toward FDA approval for treating suicidal depression.

The FDA has granted Fast Track designation to Nacuity Pharmaceuticals' NPI-001 (N-acetylcysteine amide) tablets for retinitis pigmentosa (RP) treatment.

Jazz Pharmaceuticals is focusing on expanding its oncology pipeline, with key developments expected for zanidatamab and Zepzelca.

Recce Pharmaceuticals initiates a pivotal Phase 3 clinical trial in Indonesia for RECCE 327 topical gel, aimed at treating diabetic foot infections.

Kenneth Myszkowski, CFO of Arrowhead Pharmaceuticals, has sold $893,095 worth of company stock, retaining 455,433 shares. The sales, part of a pre-established trading plan, were made to cover tax obligations. Arrowhead is advancing in pharmaceutical developments and strategic partnerships, with significant clinical trials underway.

CASI Pharmaceuticals will host a live conference call and webcast on May 21, 2025, to provide updates on its business operations and clinical pipeline developments.

MAIA Biotechnology's lead candidate, THIO, is currently in Phase II clinical trials, evaluating its potential in treating patients with non-small cell lung cancer.

Rhythm Pharmaceuticals reports preliminary unaudited net revenues of approximately $42 million for Q4 2024 and $130 million for full year 2024 from global IMCIVREE® sales.

Conduit Pharmaceuticals has successfully completed Phase I of its strategic collaboration with Sarborg Limited, focusing on integrating AI and cybernetics in drug development processes.

MIRA Pharmaceuticals' Ketamir-2 shows 60% greater efficacy than gabapentin in preclinical studies for chemotherapy-induced neuropathic pain.

EyePoint Pharmaceuticals initiates the LUGANO Phase 3 study and prepares for the LUCIA study for wet AMD, marking progress in TKI-based treatments.

Algernon Pharmaceuticals has entered into agreements to acquire NoBrainer Imaging Centers, gaining exclusive rights to establish Alzheimer's diagnostic and treatment clinics across Canada and select U.S. markets.

NRx Pharmaceuticals' methodology for training and monitoring study site raters demonstrates higher interrater reliability (IRR) on the MADRS depression scale.

Alkeus Pharmaceuticals Inc. has announced encouraging interim results from the TEASE-3 study, showing that gildeuretinol (ALK-001) halted the progression of early-stage Stargardt disease in three teenagers for up to 6 years. This marks a significant advancement in treating a disease that leads to vision loss and blindness due to a genetic mutation causing material buildup in the retina.

Lipella Pharmaceuticals completes the first cohort dosing in its Phase 2a trial of LP-310 for Oral Lichen Planus (OLP).

Xenon Pharmaceuticals is progressing its Phase 3 epilepsy program with azetukalner, anticipating topline data from the X-TOLE2 study in the second half of 2025.

KalVista Pharmaceuticals will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on September 19, 2024, to discuss its clinical programs.

LyoWave Inc. received a $304,436 Phase I SBIR grant from the National Science Foundation to advance its high-frequency microwave heating technology for pharmaceutical lyophilization.

60 Degrees Pharmaceuticals (NASDAQ: SXTP) has received IRB approval for a Phase II clinical trial evaluating ARAKODA® (tafenoquine) as a treatment for chronic babesiosis. The study, targeting a potential market of 400,000 U.S. patients, aims to address an unmet medical need for this expanding tick-borne disease, with patient enrollment scheduled to begin in Q3 2025.

Nexus Pharmaceuticals has received FDA approval for Tacrolimus Injection, expanding treatment options for organ transplant patients requiring immunosuppression.